PROKARIUM
7.2.2024 13:01:36 CET | Business Wire | Press release
Prokarium, a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic biology, today announces the dosing of the first patient in their PARADIGM-1 Phase I/Ib clinical trial in non-muscle invasive bladder cancer (NMIBC) patients (NCT06181266).
The study is being conducted at multiple clinical sites across the United States and will initially evaluate the safety of a single intravesical administration of their investigational immunotherapy, ZH9, in NMIBC patients. The study will further investigate and characterize clinical efficacy of the ZH9 treatment regimen in pre-planned expansion cohorts under the same IND.
“Dosing our first patient in the clinical trial is an exciting milestone,” said Dr. Josefin-Beate (Josi) Holz, CMO of Prokarium. “It translates our scientific promises into practical advancements, as we strive to transform the treatment paradigm for patients with NMIBC.”
Dr. Daniel Zainfeld, Urology San Antonio, commented, “We are excited to have dosed our first patient in Prokarium’s PARADIGM-1 study. The trial provides us the opportunity to explore an innovative treatment approach for our NMIBC patients who are facing significant gaps in available effective treatment options.”
Kristen Albright, CEO of Prokarium, remarked, "We are grateful to the patients and urologists involved in the PARADIGM-1 clinical trial. This achievement represents a pivotal moment for Prokarium as we introduce Living Cures, a novel class of immunotherapies built with synthetic biology.”
About Prokarium
Prokarium is a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic biology. Prokarium’s lead program, currently advancing in US clinical trials for bladder cancer, is a single-dose therapy redesigning the treatment paradigm for patients. The Company’s Living Cures platform aims to transform precision medicine into off-the-shelf programmable therapeutics, promising a new class of immunotherapies with a goal of equitable access. Prokarium is based in London, UK. For further information, visit https://www.prokarium.com.
About ZH9
ZH9, a proprietary bacterial immunotherapy under investigation in the PARADIGM-1 clinical trial (NCT06181266) in the United States, seeks to redesign the treatment paradigm for non-muscle invasive bladder cancer patients through a single-dose intravesical induction regimen.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207504370/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bitcoin Suisse Advances Middle East Expansion, Receiving Financial Services Permission in Abu Dhabi7.7.2026 09:15:00 CEST | Press release
Premium virtual assets pioneer BTCS (Middle East) Ltd. is now fully authorized by the Financial Services Regulatory Authority (FSRA) of ADGM, enabling regulated institutional services across the UAE. Building on its position as Switzerland’s leading crypto financial services provider, Bitcoin Suisse is further accelerating its international expansion. Bitcoin Suisse Group’s subsidiary, BTCS (Middle East) Ltd. (“BTCS ME”) has received Financial Services Permission (FSP) from the Financial Services Regulatory Authority (FSRA) of ADGM, the international financial centre of Abu Dhabi, marking another significant step toward the Group’s international growth strategy becoming a leading global wealth management partner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707864200/en/ Ceyda Majcen, Chief Executive Officer and SEO of BTCS ME, leads Bitcoin Suisse Group's expansion in the Middle East and brings extensive, long-standing
Alpaca Completes EEA Passporting to 29 Countries, Expanding Access to Regulated Investment Services Across Europe7.7.2026 09:00:00 CEST | Press release
Alpaca now provides regulated, localized investment services across the European Economic Area Alpaca, a global leader in brokerage infrastructure APIs, today announced that it has completed the process to passport its regulated and localized investment services across 29 countries in the EEA (European Economic Area) through its Spain-based EEA hub. The completion of EEA passporting enables Alpaca to extend the regulatory foundation established through its European entity, which is authorized and registered with Spain’s Comisión Nacional del Mercado de Valores (CNMV), across the EEA under the MiFID II framework. Together with Alpaca’s regulated UK entity, this milestone strengthens Alpaca’s ability to support fintechs, financial institutions, and enterprise partners building regulated investment products across Europe, reaching a market of nearly 500 million people. The passported countries include Austria, Belgium, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finla
Capvidia Announces 2026 R1 Software Release to Strengthen MBD Readiness, QIF Workflows, and Digital Thread Automation7.7.2026 09:00:00 CEST | Press release
Latest release brings MBDReady Check into Creo, expands QIF-based Weld Analysis for NX, improves inspection workflows, and adds STEP AP242 Edition 3 compatibility. Capvidia, a provider of Model-Based Definition (MBD), Model-Based Enterprise (MBE), and CAD interoperability software, today announced Capvidia 2026 R1, the latest version of its software portfolio for manufacturers, OEMs, suppliers, and quality organizations. Built with more than 5,600 development hours, Capvidia 2026 R1 includes a combination of over 400 new features, improvements, customer-requested enhancements, and bug fixes across the Capvidia product portfolio. The release helps manufacturers make model-based workflows more practical, validated, and automation-ready. Capvidia 2026 R1 introduces MBDReady Check inside MBDConnect for Creo, expands QIF-based Weld Analysis for Siemens NX, improves Bill of Characteristics and 2D ballooning workflows in MBDVidia, strengthens semantic recognition for machine-readable inspecti
Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns7.7.2026 07:00:00 CEST | Press release
World’s most extensive skin quality profiling survey of more than 11,000 people across Europe, Asia, and the Americas finds that nine out of ten people are affected by skin quality concerns, with the most important attributes of good skin quality identified as smooth, hydrated and glowing skin1 Results show that skin quality has an impact on quality of life for 85% of people, with more than a third feeling self-conscious, insecure or anxious due to poor skin quality1 In response to clinicians’ calls for a universal assessment tool to help address these concerns, Galderma supported leading experts in the development of the Skin Quality Assessment Scale; a holistic, science-based tool to evaluate skin quality comprehensively and guide personalized, long-term treatment planning2 At Galderma, we champion skin quality by providing insights, tools, and solutions to better understand and address a wide spectrum of concerns, helping people take pride and feel comfortable in their own skin at e
Morinaga Milk Achieves Self-Affirmed GRAS Status for LAC-Living+™, Expanding U.S. Opportunities for Its Postbiotic Ingredient7.7.2026 04:00:00 CEST | Press release
Clinical evidence–backed postbiotic supports mood and well-being with formulation flexibility for diverse applications Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy and functional ingredient company, today announced that it has achieved self-affirmed GRAS (Generally Recognized As Safe) status in the United States for LAC-Living+™ (L. helveticus MCC1848), its proprietary postbiotic ingredient. This milestone expands the commercial availability of LAC-Living+ in the U.S. market and enables its use in dietary supplements, functional foods, and beverages, supporting the development of products designed to address growing consumer demand for health and well-being solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706806943/en/ Growing Interest in Postbiotics and Mental Well-Being Consumer interest in proactive health management has expanded significantly in recent years, alongside increasing aw
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom